Last reviewed · How we verify

acetaminophen plus codeine — Competitive Intelligence Brief

acetaminophen plus codeine (acetaminophen plus codeine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic. Area: Pain management.

phase 3 Opioid analgesic Opioid receptors Pain management Small molecule Live · refreshed every 30 min

Target snapshot

acetaminophen plus codeine (acetaminophen plus codeine) — Nova Scotia Health Authority. Acetaminophen acts as a non-selective COX inhibitor, while codeine exerts its effects through opioid receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
acetaminophen plus codeine TARGET acetaminophen plus codeine Nova Scotia Health Authority phase 3 Opioid analgesic Opioid receptors
SAMIDORPHAN L-MALATE SAMIDORPHAN L-MALATE marketed Atypical Antipsychotic [EPC] dopamine and serotonin type 2 (5HT2) receptors, opioid receptors 2021-01-01
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
NALBUPHINE HYDROCHLORIDE NALBUPHINE HYDROCHLORIDE marketed kappa opioid receptors, mu opioid receptors 1979-01-01
Methadone Hydrochloride METHADONE Specgx Llc marketed Opioid Agonist mu-opioid receptors, NMDA receptor 1947-01-01
morphine ,ketorolac morphine ,ketorolac Jose Antonio Bernia Gil marketed Opioid analgesic + NSAID combination Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
NB NB Orexigen Therapeutics, Inc marketed Combination antiobesity agent (opioid antagonist + norepinephrine-dopamine reuptake inhibitor) Opioid receptors (naltrexone); norepinephrine and dopamine transporters (bupropion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic class)

  1. Alza Corporation, DE, USA · 3 drugs in this class
  2. Labopharm Inc. · 3 drugs in this class
  3. University of Rochester · 3 drugs in this class
  4. Purdue Pharma LP · 3 drugs in this class
  5. Institute of Child Health · 2 drugs in this class
  6. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2 drugs in this class
  7. Fujian Cancer Hospital · 2 drugs in this class
  8. Children's Hospital of Fudan University · 2 drugs in this class
  9. AdventHealth · 2 drugs in this class
  10. Danish University of Pharmaceutical Sciences · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). acetaminophen plus codeine — Competitive Intelligence Brief. https://druglandscape.com/ci/acetaminophen-plus-codeine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: